1. Home
  2. LITE vs ARGX Comparison

LITE vs ARGX Comparison

Compare LITE & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lumentum Holdings Inc.

LITE

Lumentum Holdings Inc.

HOLD

Current Price

$914.36

Market Cap

61.1B

ML Signal

HOLD

Logo argenx SE

ARGX

argenx SE

HOLD

Current Price

$848.62

Market Cap

58.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LITE
ARGX
Founded
2015
2008
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
61.1B
58.4B
IPO Year
2015
2017

Fundamental Metrics

Financial Performance
Metric
LITE
ARGX
Price
$914.36
$848.62
Analyst Decision
Buy
Strong Buy
Analyst Count
15
19
Target Price
$645.43
$1,008.56
AVG Volume (30 Days)
4.6M
272.9K
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
104.56
N/A
EPS
2.59
N/A
Revenue
$1,247,700,000.00
N/A
Revenue This Year
$79.88
$44.39
Revenue Next Year
$66.61
$20.84
P/E Ratio
$339.93
$33.69
Revenue Growth
24.57
N/A
52 Week Low
$111.20
$650.01
52 Week High
$1,085.68
$953.58

Technical Indicators

Market Signals
Indicator
LITE
ARGX
Relative Strength Index (RSI) 58.22 43.72
Support Level $810.55 $833.82
Resistance Level $945.25 $851.88
Average True Range (ATR) 77.86 21.60
MACD 19.66 -1.61
Stochastic Oscillator 87.11 25.93

Price Performance

Historical Comparison
LITE
ARGX

About LITE Lumentum Holdings Inc.

Lumentum Holdings Inc is a California-based technology firm. The company provides two types of optical and photonic products: optical components that are used in telecommunications networking equipment, and commercial lasers for manufacturing, inspection, and life-science lab uses. Its segments are Optical Communications and Commercial Lasers. The firm is also expanding into new optical applications, such as 3-D sensing laser diode for consumer electronics. It generates maximum revenue from the OpComms segment. The OpComms segment products include a wide range of components, modules, and subsystems to support customers including carrier networks for access (local), metro (intracity), long-haul, and submarine (undersea) applications.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: